ETF Objective

The Fund seeks investment results that correspond to the performance, before fees and expenses, of the STOXX Global Broad Infrastructure Index. The Index reflects the performance of a selection of equity securities of infrastructure-related companies that are domiciled in developed and emerging markets around the world.

Stock Chart

as of 4:10 PM ET 09/24/2021

Performance

  • 1 Week
  • -0.66%
  • 1 Month
  • -2.73%
  • 3 Months
  • -1.54%
  • 1 Yr Return
  • +16.00%
  • 5 Yr Return
  • +25.53%

Sector Breakdown

Utilities 25.68%
Industrials 24.48%
Telecommunications 16.68%
Consumer Services 11.50%
Oil & Gas 7.45%
Financials 5.91%
Health Care 3.44%
Technology 0.27%

Geographic Exposure

United States 41.34%
Canada 15.20%
Japan 8.54%
Germany 6.84%
United Kingdom 4.84%
Spain 4.18%
Australia 4.09%
Italy 3.60%
France 2.93%
Unidentified 1.75%
Hong Kong 1.32%
Thailand 1.12%
Denmark 1.10%
India 1.05%
Mexico 0.58%
New Zealand 0.44%
Philippines 0.39%
Brazil 0.34%
Malaysia 0.31%
Switzerland 0.30%
Netherlands 0.23%
South Africa 0.18%
Russian Federation 0.15%
Luxembourg 0.15%
China 0.12%
Singapore 0.11%
Greece 0.09%
Austria 0.07%
Belgium 0.05%
Indonesia 0.05%
Chile 0.04%
Finland 0.03%
Taiwan 0.03%
Korea 0.03%
Poland 0.00%

Top 10 Holdings

Symbol Company Name % Of Assets
CNR Canadian National Railway Co ORD 4.25%
CMCSA Comcast Corp ORD 4.18%
DPW Deutsche Post AG ORD 3.54%
VZ Verizon Communications Inc ORD 3.42%
T AT&T Inc ORD 2.94%
ENB Enbridge Inc ORD 2.87%
IBE Iberdrola SA ORD 2.62%
ENEL Enel SpA ORD 2.56%
NEE Nextera Energy Inc ORD 2.48%
CP Canadian Pacific Railway Ltd ORD 2.34%

ETF Overview

Sponsor Flexshares
iNav Ticker C6X4
Inception Date 10/08/2013
Name FlexShs:STOXX Gl Brd Inf
CUSIP 33939L795
Prospectus Date 03/01/2021

ETF Characteristics

Market Capitalization 79.21 B
Total Net Assets 2.82 K
Management Fee 0.47%
Administration Fee 0.00%
Asset Class Equity
Sub Asset Class Global Infrastructure Funds
Number Of Holdings 213
Expense Ratio 0.47
Dividend 0.57
Dividend Frequency Quarterly

LATEST NEWS

Recent Articles from TheStreet

wynn resorts broll

Jim Cramer Talks Macao With Wynn Resorts CEO

Matthew Maddox argues China's crackdown will lead to better regulation.

Tesla Lead

Electric Vehicle Checkpoint: Experts Say EV Revolution is Here

See the latest news for the top stocks in the electric vehicle space including Tesla, Ford, General Motors, Li Auto and more.

Nikola

Tim Collins on How to Trade Nikola

Technical setups and short interest make much hated name volatile, and therefore interesting.

Chinese Firms Should Face Faster US Stock Delisting Over Audit Rules, SEC Chairman Gary Gensler Tells Lawmakers

Jim Cramer: Gensler's Plate is Very Full

SEC Chairman is key player in efforts to rein in ceaseless financial engineering.

stocks rise asset management sh

Cramer's Mad Money Recap: Advanced Micro Devices, Nvidia, Thor

Jim Cramer has your game plan for next week, which he says will be the calm before the earnings season storm.

Jim Cramer: Starbucks Needs More Traffic in Stores

Starbucks Resists Union Effort in New York Region: Report

Starbucks reportedly said it will raise wages and benefits and a union isn’t needed, to employees at three stores in Buffalo New York.

Exxon Mobil

Exxon, Occidental, Baker Hughes Make Goldman Turnaround List

Exxon has 'reduced costs, surprised to the downside on capital spending, outperformed our expectations in downstream/chemicals,' Goldman said.

videoblocks-a-series-of-fullhd-close-up-rotating-slider-dollymacro-shots-of-the-surface-of-computer-hardware-parts-chipsmotherboardcpucurcuits-close-up-macro-computer-chips-circuits-surface-rotating-dolly_s_mt0i43g_1080__D

Jim Cramer is Tired of the Weak Response to Chip Shortages

Companies need to forget about help from Washington and step up to the plate.

Microsoft Lead

Why 'Sarge' Guilfoyle Isn't Selling His Microsoft

Sharp management and strength across its business lines are keys to software giant.

Why Charles River Labs Is the Biotech Stock to Buy: Jim Cramer

Bret Jensen: Paratek Deal Shows Promise

While antibiotics are usually less profitable and slower to develop market share than other drugs, Paratek has a key factor in its favor.